Insurers scrutinize drug costs after $84,000 Sovaldi surprise

NEW YORK/LOS ANGELES (Reuters) - Shocked by the rapid adoption of a new $84,000 hepatitis C treatment, U.S. health insurers are trying to make sure they aren’t blindsided by other drugs being developed and are looking for ways to limit their use from the day they are launched.

via Reuters: Health News Read More Here..